A leading group of European health, research and policy organisations have today sent a joint letter to EU member states’ permanent representatives, urging them to support pro-transparency amendments to Clinical Trials Regulation that Members of the European Parliament (MEPs) voted for in May 2013. The letter was signed by a number of organisations including: The International Society of Drug Bulletins, The Nordic Cochrane Centre, The Medicines in Europe Forum, Health Action International Europe, The Association Internationale de la Mutualité and The Transatlantic Consumer Dialogue.

This follows a briefing document sent last week by AllTrials and a number of European hospital and patient groups to prominent European contacts explaining the importance of retaining proposed amendments which support clinical trial transparency. AllTrials invites other European organisations to add their signature to the briefing document (PDF) which we plan to send again to European contacts ahead of final discussions on 12th December 2013. Please contact us for more information.